<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117038</url>
  </required_header>
  <id_info>
    <org_study_id>TA-019</org_study_id>
    <nct_id>NCT01117038</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Avanafil and Enalapril or Amlodipine</brief_title>
  <official_title>A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the change in the blood pressure and pulse rate,&#xD;
      pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the change in standing blood pressure after dosing</measure>
    <time_frame>-0.5, -0.25, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the pharmacokinetic parameters of taking avanafil with enalapril</measure>
    <time_frame>before dosing and after dosing at the hours of 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 18, 24, 36, 48</time_frame>
    <description>AUCc-tau Cmax Cmin Tmax AUC0-t AUC0-inf t1/2 Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the change in sitting and lying blood pressure and pulse rate after dosing</measure>
    <time_frame>-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of enalapril on blood pressure and pulse rate</measure>
    <time_frame>-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the pharmacokinetic parameters of taking avanafil with amlodipine</measure>
    <time_frame>before dosing and after dosing at the hours of 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 18, 24, 36, 48</time_frame>
    <description>AUCc-tau Cmax Cmin Tmax AUC0-t AUC0-inf t1/2 Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of amlodipine on blood pressure and pulse rate</measure>
    <time_frame>-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>enalapril and avanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine and avanafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil and enalapril</intervention_name>
    <description>enalapril twice a day for 11 days avanafil/placebo once a day for 2 days</description>
    <arm_group_label>enalapril and avanafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil and amlodipine</intervention_name>
    <description>amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days</description>
    <arm_group_label>amlodipine and avanafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily consent to participate in the study (informed consent form [ICF] must be&#xD;
             signed and dated prior to any study related assessments).&#xD;
&#xD;
          2. Adult male subjects of 40 to 65 years of age, inclusive.&#xD;
&#xD;
          3. A body weight of at least 50 kg and a body mass index (BMI) between 18 and 32 kg/m2,&#xD;
             inclusive [BMI will be calculated as weight in kg/(height in m)2].&#xD;
&#xD;
          4. Subjects are able to communicate with the Investigator, and to understand and comply&#xD;
             with all requirements of study participation.&#xD;
&#xD;
          5. Medically healthy, with no clinically significant screening results (e.g., laboratory&#xD;
             profiles, medical histories, ECGs, physical examinations, etc.), in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history or presence of significant cardiovascular (including thromboembolic&#xD;
             disorders), neurological, hematological, psychiatric, hepatic, gastrointestinal,&#xD;
             pulmonary, endocrine, immunologic, or renal disease, or other condition known to&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of drugs or&#xD;
             place the subjects at increased risk as determined by the Investigator.&#xD;
&#xD;
          2. Any clinically significant laboratory abnormalities as judged by the Investigator.&#xD;
&#xD;
          3. A predisposition to priapism, such as subjects with sickle cell disease or blood&#xD;
             dyscrasias.&#xD;
&#xD;
          4. Known history of cardiovascular or cerebrovascular event, or any history of angina.&#xD;
&#xD;
          5. History of fainting or vasovagal hypotension.&#xD;
&#xD;
          6. History or ECG evidence of any high-risk arrhythmia or ECG judged by the Investigator&#xD;
             to be clinically significant.&#xD;
&#xD;
          7. Hypertrophic obstructive or other clinically significant cardiomyopathy, moderate or&#xD;
             severe cardiac valvular disease.&#xD;
&#xD;
          8. Subjects whose pulse is lower than 50 bpm at screening.&#xD;
&#xD;
          9. Acute illness, especially any infection, within 2 weeks of dosing.&#xD;
&#xD;
         10. Supine systolic blood pressure &lt;/= 100 or &gt;/= 140 mmHg; supine diastolic blood&#xD;
             pressure &lt;/= 50 or &gt;/= 95 mmHg at screening (2 rechecks are allowed).&#xD;
&#xD;
         11. Subjects with orthostatic hypotension (as evidenced by a reduction of 30 mmHg or more&#xD;
             in systolic blood pressure, reduction of 20 mmHg or more in diastolic blood pressure,&#xD;
             or evidence of cerebral hypoperfusion upon standing from a seated position).&#xD;
&#xD;
         12. Any history of bipolar disorder or psychosis, history of psychiatric hospitalization,&#xD;
             greater than one lifetime episode of major depression.&#xD;
&#xD;
         13. Hemoglobin &lt; 12.0 g/dL.&#xD;
&#xD;
         14. Positive urine drug test, positive urine alcohol test, or positive urine cotinine test&#xD;
             at screening or at check-in on Day -1.&#xD;
&#xD;
         15. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibodies (HCV) at screening.&#xD;
&#xD;
         16. Any history or presence of alcoholism or drug or substance abuse within 18 months or&#xD;
             as defined by the Investigator.&#xD;
&#xD;
         17. Allergy to or previous adverse events with PDE5 inhibitors, ACE inhibitors, calcium&#xD;
             channel blockers, or their constituents.&#xD;
&#xD;
         18. Use of any prescription or over-the-counter (OTC) medication, including herbal&#xD;
             products, within the 14 days prior to Day 1 and throughout the study. Up to 2 g per&#xD;
             day of acetaminophen is allowed at the discretion of the Investigator.&#xD;
&#xD;
         19. Use of any drug in Appendix 1 (drugs known to interfere with metabolism by the CYP450&#xD;
             3A4 enzyme) within 30 days prior to Day 1.&#xD;
&#xD;
         20. Blood donation or significant blood loss within 56 days prior to Day 1.&#xD;
&#xD;
         21. Plasma donation within 14 days prior to Day 1.&#xD;
&#xD;
         22. Any use of tobacco or nicotine products within 6 months prior to Day 1.&#xD;
&#xD;
         23. Any subject who received an investigational drug within 30 days or six half-lives,&#xD;
             whichever is longer, prior to Day 1.&#xD;
&#xD;
         24. Involvement in the planning and conduct of the study (applies to both VIVUS or&#xD;
             designee staff, or staff at the investigational site).&#xD;
&#xD;
         25. Previously participated in a trial with avanafil.&#xD;
&#xD;
         26. Subjects who report having difficulty swallowing tablets, capsules, etc.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyin Yee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <keyword>ED</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Enalapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

